Milrinon Hikma (Milrinone)

Milrinone, the active ingredient in Milrinon Hikma, is a phosphodiesterase‑3 inhibitor presented as an intravenous formulation for intravenous use. It is employed in the short‑term management of acute decompensated heart failure and cardiogenic shock in hospitalized patients. GNH USA supplies Milrinon Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as a cardiac inotropic and vasodilator, improving cardiac output in acute heart failure states.

Acute decompensated heart failure: enhances myocardial contractility and reduces afterload to improve symptoms. Cardiogenic shock: provides rapid inotropic support to stabilize hemodynamics. Low cardiac output syndrome: increases cardiac output when conventional therapy is insufficient.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: reduced blood pressure due to vasodilation. - Headache: often associated with lowered vascular tone. - Tachyarrhythmia: increased heart rate or irregular rhythm. - Nausea: gastrointestinal discomfort. - Flushing: warm sensation and reddening of skin. - Diarrhea: loose stools in some patients.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked drop in blood pressure requiring intervention. - Thrombocytopenia: low platelet count leading to bleeding risk. - Anaphylactic reactions: rare severe allergic response. - Death: possible in cases of profound hemodynamic collapse.

Milrinone requires careful monitoring and specific safety measures.

Monitor blood pressure: watch for hypotension and adjust infusion rate. Observe cardiac rhythm: detect arrhythmias promptly. Assess renal function: dose may need adjustment in renal impairment. Avoid use in severe aortic stenosis: risk of excessive vasodilation. Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Concurrent phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma levels, raising toxicity risk. - Other potent inotropes: synergistic action can precipitate dangerous arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic response, requiring dose titration. - Diuretics: volume depletion can exacerbate hypotension. - Digoxin: combined use may increase risk of arrhythmias; monitor serum levels.